CRD-4730

Phase 2Small molecule

CRD-4730 is one of 6 small molecule programs targeting Heart Failure With Reduced Ejection Fraction (HFrEF). It is currently in Phase 2.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

Heart Failure With Reduced Ejection Fraction (hfref)Recruiting

Catecholaminergic Polymorphic Ventricular TachycardiaTerminated

Heart Failure With Reduced Ejection Fraction (hfref)Phase 2

Recruiting

Catecholaminergic Polymorphic Ventricular TachycardiaPhase 2

Terminated

Competition

Competitive Landscape

5 competitors in Catecholaminergic Polymorphic Ventricular Tachycardia

#DrugCompanyPhaseTrials

CRD-4730

CCardurion Pharmaceuticals, Inc.

Phase 2

2 2

Atropen

FFresenius Kabi Taiwan Ltd.

Preclinical

1 3

Beta Blocker

WWeill Medical College of Cornell University

Preclinical

1 4

Tambocor

AAlvogen Korea

Preclinical

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q2 2027

Phase 2Recruiting

Catecholaminergic Polymorphic Ventricular Tachycardia

NCT06658899

Q3 2028

Phase 2Recruiting

Heart Failure With Reduced Ejection Fraction (hfref)

NCT07750873

Clinical

Trials by Indication[1]

Catecholaminergic Polymorphic Ventricular Tachycardia2 trials

Effectiveness of CRD-4730 in Participants With Catecholaminergic Polymorphic Ventricular Tachycardia (CPVT)

Terminated·CCardurion Pharmaceuticals, Inc.·Phase 2·NCT06005428·7 enrolled

A Phase 2, Double-Blind, Repeat-Dose, Placebo-Controlled Crossover Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of CRD-4730 In Participants With Catecholaminergic Polymorphic Ventricular Tachycardia

Recruiting·CCardurion Pharmaceuticals, Inc.·Phase 2·NCT06658899·12 enrolled

Heart Failure With Reduced Ejection Fraction (HFrEF)1 trial

A Phase 2, Randomized, Double-Blind, Placebo-Controlled Trial to Evaluate the Efficacy, Safety, and Tolerability of CRD-4730 in Patients With Heart Failure With Reduced Ejection Fraction (HFrEF)

Recruiting·CCardurion Pharmaceuticals, Inc.·Phase 2·NCT07750873·525 enrolled

Sources

References

[1]
ClinicalTrials.gov — 3 trial records for CRD-4730. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — CRD-4730 compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for CRD-4730. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Cardurion Pharmaceuticals, Inc. company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Phase 2[1]
Company: CCardurion Pharmaceuticals, Inc.

CRD-4730

Status by Indication[3][1]

Competitive Landscape

Expected Milestones

Q2 2027

Q3 2028

Trials by Indication[1]

Catecholaminergic Polymorphic Ventricular Tachycardia2 trials

Heart Failure With Reduced Ejection Fraction (HFrEF)1 trial

References

Drug Info

Quick Facts

Related News